ArticleScientific reports2025
Phytochemical analysis and antimicrobial activity of Ganoderma lucidum against selected bacteria and fungi of medical importance.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methodological heterogeneity in mushroom extract antimicrobial research (2012-2025): a structured narrative evidence gap analysis and proposed reporting framework.Folia microbiologica · 2026Review
- Prevalence and antibiotic resistance pattern of Staphylococcus spp. isolated from acne, and disrupting their antimicrobial resistance: unveiling the potential of Ganoderma lucidum extract.Journal, genetic engineering & biotechnology · 2026Article
- Soil microbial community succession and physicochemical property changes affectFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ganoderma lucidum is a rapidly growing mushroom, wood-colonizing fungus belonging to the phylum Basidiomycota. G. lucidum exhibits a wide range of pharmacological properties such as antimicrobial and anticancer activities. However, with its potentials, the antibacterial and antifungal effects of its purified compounds have been relatively understudied. This study aims to investigate the phytochemical analysis and antimicrobial effects of Ganoderma lucidum against selected bacteria and fungi of medical importance. Molecular Identification was done by targeting the internal transcribed spacer (ITS) region of the rDNA gene. The phytochemical composition of the extract was determined using gas chromatography-mass spectrometry (GC-MS). Antimicrobial testing was performed using the agar well diffusion method to evaluate the inhibitory effects of the extract against select microorganisms. Gas chromatography-mass spectrometry (GC-MS) analysis identified 44 compounds in the methanol and 29 compounds in the aqueous extracts of the mushroom. Antimicrobial analysis demonstrated significant inhibitory effects against Staphylococcus aureus (MIC: 10.5 mm), Escherichia coli (MIC: 33.5 mm), and Candida albicans (MIC: 16 mm), as well as Pseudomonas aeruginosa (MIC: 15 mm). The methanol extract showed moderate effects against Rhizopus sp. at concentrations of 5 and 10 mg/ml with (MIC: 16 mm and 18 mm) but showed resistance to the chloramphenicol. However, Aspergillus flavus, Aspergillus niger and Penicillium showed resistance against Ganoderma lucidum. Overall, this findings show the extracts has the potential for combating the growing threat of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.